Objective:Evaluation on the safety and efficacy of Tirofiban in patients with ST elevation acute coronary syndrome(STEACS) treated by primary percutaneous coronary intervention(PCI). Methods 158 consecutive patients with STEACS were observed form 2010 to 2012,All the individuals were performed PCI within 12 hours after onset of STEACS. 158 cases were divided into two groups:the control group (n=80), the test group (n =78)received the same treatment as group plus Tirofiban. All patients took aspirin,clopidogrel and injected heparin subcutaneously.Thrombolysis in acute myocardial infarction (TIMI) grade was Observed, The major adverse cardiac events(MACE) at 30 days and bleeding complications were studied. Results:All the individuals of both group had no the major adverse cardiac events.In the test group,the occurance of slow-reflow were lower than those in control group,there was significant difference in both groups(P<0.05).4 cases occurred severe bleeding adverse reactions in test group(5.13%),3 cases occurred severe bleeding adverse reactions in control group (3.75%),there was no significant difference(P>0.05). Conclusion: Using Tirofiban after PCI in STEACS patients, being safety and efficacy,can improve TIMI flow of infarction related artery in patients with STEACS by PCI.
ST elevation acute coronary syndromePercutaneous coronary interventionTirofibanEfficacySafety
NETL
NSTL
万方数据
